Publication
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Amir T Fathi, Alexander E Perl, Geoffrey G Fell, Brian A Jonas, Brittany K Ragon, Alice S Mims, Uma Borate, Gabriel N Mannis, Karen Quillen, Maximilian Stahl, Brandon J Aubrey, Paul Koller, Andrew S Artz, Monzr M Al Malki, Anthony S Stein, Guido Marcucci, Mary Linton B Peters, Timothy A Graubert, Peter Westervelt, Philip C Amrein, Hanno R Hock, Andrew M Brunner, Gabriela Hobbs, Rupa Narayan, Michelle H Lee, Peter G Miller, Alyssa L Watson, Richard Hao, Abigail C Marola, Jennifer Lombardi-Story, Shilton Dhaver, Michael R Grunwald, Yi-Bin Chen, Matthew J Weinstock, Andrew H Matthews, Ian McGovern, Brent L Wood, Christopher S Hourigan, Donna S Neuberg, Areej El-Jawahri, Ibrahim Aldoss
- Source
- PubMed
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260915-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care utilization. For patients who are ineligible for induction chemotherapy, hypomethylating…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04801797registry_reference1.00
Candidate 1
- cancerLeukemiadictionary0.60
Registered trialsNCT04801797
Curated evidence
Evidence citing this paper (0)
Data not yet available